Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration

British Journal of Clinical Pharmacology, Supplement

Volumn 46, Issue 1, 1998, Pages 13-18

  Tiseo, P J ^a   Rogers, S L ^a   Friedhoff, L T ^a  

^a EISAI INC   (United States)

Author keywords

Donepezil; Evening dose; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; ENZYME INHIBITION; EQUILIBRIUM DIALYSIS; ERYTHROCYTE MEMBRANE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HYSTERESIS; LETHARGY; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RADIOENZYMATIC ASSAY; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; TIME; ULTRAVIOLET SPECTROSCOPY;

EID: 0032424681     PISSN: 02643774     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.0460s1013.x     Document Type: Article

References (14)

1. Yamanishi Y, Ogura H, Kosasa T, Araki S, Sawa Y, Yamatsu K. Inhibitory action of E2020, a novel acetylcholinesterase inhibitor, on cholinesterase: comparison with other inhibitors. In Basic, Clinical, and Therapeutic Aspects of Alzheimer's and Parkinson's Diseases, Volume 2, eds Nagatsu T, Yoshida M, Fisher A. New York: Plenum Press, 1990: 409-413.
2. Rogers SL, Yamanishi Y, Yamatsu K. E2020 - the pharmacology of a piperidine cholinesterase inhibitor. In Chalinergic Basis for Alzheimer Therapy, eds Becker R, Giacobini E. Boston: Birkhäuser, 1991: 314-320.
3. Rogers SL, Friedhoff LT, the Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicenter, randomized, double-blind, placebo-controlled trial. Dementia 1996; 7: 293-303.
4. Rogers SL, Duody RS, Mohs RC, Friedhoff LT. E2020 produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease (AD): results of a 30-week Phase III trial. Neurology 1996; 46: A217 (S14.001).
5. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, the Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease, Neurology 1998; 50: 136-145.
6. Rogers SL, Doody RS, Mohs R, Friedhoff LT, the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer's disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998; 158: 1021-1031.
7. Rogers SL, Perdomo C, Friedhoff LT. Clinical benefits are maintained during long-term treatment of Alzheimer's disease with the acetylcholinesterase inhibitor, E2020. Eur Neuropsychopharmacol 1995; 5: 386 (P-8-21).
8. Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a multicentre open label extension trial. Eur Neuropsychopharmacol 1998; 8: 67-75.
9. Lee JW, Rogers SL, Friedhoff LT, Stiles MR, Cooper NM. Validation and application of an HPLC method for the determination of 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl] methyl piperidine HCl (E2020) in human plasma. Pharm Res 1992; 9: S350.
10. Hulse JG, Rogers SL, Friedhoff LT, Sukovaty R, Pedersen JE, Lee JW. A radioenzyme assay of acetylcholinesterase activity in red blood cells and its correlation with 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl] methyl piperidine HCl. Pharm Res 1992; 9: S228.
11. Forgue TS, Reece PA, Sedman AJ, de Vries TM. Inhibition of tacrine oral clearance by cimetidine. Clin Pharmacol Ther 1996; 59: 444-449.
12. Sharpless NS, Thai LJ. Plasma physostigmine concentrations after oral administration. Lancet 1985; i: 1397-1398.
13. Anand R, Hartman RD, Hayes PE, Gharabawi M. An overview of the development of SDZ ENA 713, a brain selective acetylcholinesterase inhibitor, in Alzheimer Disease: from Molecular Biology to Therapy, eds Becker R, Giacobini E. Boston: Birkhäuser, 1996: 239-243.
14. Rogers SL, Cooper NM, Sukovaty R, Pederson JE, Lee JN, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. Br J Clin Pharmacol 1998; 46 (Suppl. 1): 7-12.